使用新型结构和功能 MRI 评估 CFTR 调节剂治疗囊性纤维化肺病
This is a prospective, longitudinal observational study conducted at The Hospital for Sick Children (SickKids). The purpose of this study is to evaluate the ability of MRI to detect changes in lung structure and function in CF patients receiving CFTR-modulator therapy. Participants who meet eligibility criteria and consent to the study will undergo study procedures which include spirometry and body plethysmography (optional), multiple breath washout testing, MRI and measurement of quality of life. The study will consist of three to six study visits for Group 1, 2 and 3: baseline, one month (±1 week) and 6 month (±2 week) and if they re-consent then 3 additional visits of 1 year (±6 months). (2 years (±6 months) and 3 years (±6 months) follow-up. Some participants in Group 2 may transition to Group 3.
This study includes three populations of interest: Group 1: 25 healthy volunteers, Group 2: 25 patients with stable CF lung disease , Group 3: 20 patients with CF lung disease anticipated to receive treatment with CFTR-modulator therapy and Group 4: 18 patients with CF who are between 4-8 years old and are starting triple combination modulator therapy using the rapid lung and abdominal imaging methods.
研究概览
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 1X8
- The Hospital for Sick Children
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
This study includes four populations of interest: Group 1: 25 healthy volunteers, Group 2: 25 patients with stable CF lung disease and Group 3: 20 patients with CF lung disease anticipated to receive treatment with CFTR-modulator therapy and Group 4: 18 patients with CF who are between 4-8 years old and are starting triple combination modulator therapy using the rapid lung and abdominal imaging methods
描述
Inclusion Criteria:
- Participants must be greater than or equal to 4 years of age
- Informed consent by patient or parent/guardian consent and participant assent when appropriate.
- Able to perform reproducible spirometry and achieve a breath hold duration sufficient for MRI acquisition
Exclusion Criteria:
- Medical instability that would preclude the ability to undergo the required investigations
- FEV1 % predicted < 40%
- Severe claustrophobia
- Does not meet MRI screening criteria
- Cough within the past 3 days prior to study visit
- Usage of oral antibiotics within 3 weeks prior to study visit
学习计划
研究是如何设计的?
设计细节
- 观测模型:OTHER
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Group 1
Healthy participants without lung disease |
|
Group 2
Participants with stable cystic fibrosis |
|
Group 3
Participants with cystic fibrosis, anticipated to receive treatment with CFTR-modulator therapy. Please note: treatment is determined by your physician as part of your normal therapy plan. |
|
Group 4
Participants with CF who are between 4-8 years old and are starting triple combination modulator therapy using the rapid lung and abdominal imaging methods. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Reproducibility
大体时间:36 months
|
Establish the interscan reproducibility of fractional ventilation maps and 1H MRI over three and up to six visits in healthy volunteers and in patients with stable CF lung disease and compare to conventional spirometry and LCI. |
36 months
|
|
Correlation
大体时间:12 months
|
Correlate changes in lung structure and function detected by MRI imaging with clinical outcomes including FEV1 rate of decline, frequency of pulmonary exacerbations, days of IV antibiotics and hospital days to treat pulmonary exacerbation and change in health-related quality of life measures (CFQ-R scores and CF-QUEST) in the setting of patients with stable CF lung disease and those receiving CFTR-modulator therapy. |
12 months
|
|
Responsiveness
大体时间:36 months
|
Assess responsiveness of MRI to treatment effects over three and up to six visits visits in CF patients receiving CFTR-modulator therapy and compare to conventional breathing tests |
36 months
|
|
Younger cohort
大体时间:24 months
|
Extension of above objectives originally only explored in children ages 8-18 years old, to younger cohort of CF participants ages 4-8 years old at baseline prior to initiation of CFTR modulator therapy, as well as at 12 and 24 months after therapy initiation. |
24 months
|
合作者和调查者
调查人员
- 首席研究员:Giles Santyr, PhD、The Hospital for Sick Children
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Data will be shared between the two participating sites in the study. A data transfer agreement has been implemented to enable this transfer smoothly.
IPD 共享时间框架
The data will be available after enrolling the first participant and will be available for the duration of the study
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.